ABSTRACT Objective: To systematically evaluate the effect of reducing trastuzumab use time on HER-2 positive breast cancer patients. Methods:PubMed, EMBase, The Cochrane Library (Issue 5, 2018), Clinicaltrial.gov, SinoMed, CNKI, WanFang Data and VIP databases were electronically searched to collect randomized controlled trials (RCTs) of reducing trastuzumab use time on HER-2 positive breast cancer patients from inception to May 2018. Two reviewers independently screened literatures, extracted data and assessed risk of bias of included studies. Then Meta analysis was performed by RevMan 5.3 software. Results:A total of 4 RCTs involving 9 466 patients were included. The results of Meta analysis showed that: compared with control group (6 months group), the early cardiac discontinuation due to cardiotoxicity (Peto OR=2.49, 95%CI 1.83 to 3.39, P<0.000 01), the cardiac function obstacle (Peto OR=1.50, 95%CI 1.23 to 1.83, P<0.000 1), LVEF<50% (Peto OR=1.39, 95%CI 1.14 to 1.70, P=0.001) of experimental group (12 months group) was higher, the difference was statistically significant. There was no significant difference between the two groups in the efficiency and mortality rate (P>0.05). Conclusion: Current evidence showed that shortening the use of trastuzumab didn’t reduce the effect, but it could reduce cardiotoxicity. Due to the limited quality of included studies, the above conclusion still needed to be verified by more high quality studies. |